NCT07296627Recruiting
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
A Prospective Study for Chinese Newly Diagnosed Multiple Myeloma Patients Treated With Immuno-therapy in Real-world Setting
Source: ClinicalTrials.gov · Last updated 22 Dec 2025
Brief summary (registry, in English)
To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China. Leveraging the extensive patient resources of China's large center for blood disorders, the investigator will recruit approximately 500 NDMM patients to establish an NDMM patient cohort. The investigator will collect data on disease characteristics, treatment patterns, and clinical outcomes through one year of clinical follow-up. Further long-term follow-up is needed to obtain survival status and causes of death, so as to provide essential evidence for optimizing and improving patients' prognosis in clinical individualized treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 8 Dec 2025
- Start date
- 16 Jul 2025
- Primary completion date
- 15 Jul 2027
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT07296627
What you commit to
- Study type: Observational
- Planned participants: 500
- From 16 Jul 2025 to the primary completion date, 15 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Patients who did not receive any follow-up after initial diagnosis
Who the study is looking for
- Newly diagnosed multiple myeloma (NDMM)
- Plan to receive first-line immunotherapy at the respective research center
- First-line immunotherapy includes proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), or anti-CD38 monoclonal antibodies, used alone or in combination with each other or with other treatments
- Age ≥ 18 years
- Ability to understand the purpose of the study and follow-up process
- Willingness to provide signed and dated written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.